MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 regimen.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Cancer Res.

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1078-0432

ISSN (Print): 1078-0432

Publication date (Electronic): May 1 2015

Volume: 21

Issue: 9

Affiliations

[1 ] Department of Neurology, University Hospital Zurich, Zurich, Switzerland. michael.weller@usz.ch.

[2 ] Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

[3 ] Clinical Trial Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.

[4 ] Department of Neuropathology, Heinrich Heine University Düsseldorf, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

[5 ] Dr. Senckenberg Institute for Neuro-Oncology, University Hospital Frankfurt, Frankfurt, Germany.

[6 ] Department of Neurology, Heidelberg University Medical Center; National Center for Tumor Diseases Heidelberg, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

[7 ] Department of Neurosurgery, Ludwig Maximilian University of Munich, Munich, Germany.

[8 ] Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany.

[9 ] Division of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.

[10 ] Department of Neurosurgery, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

[11 ] Department of Neurosurgery, Saarland University, Homburg, Germany.

[12 ] Department of Neurology, University Hospital Bochum, Bochum, Germany.

[13 ] Department of Oncology, Medical University Vienna, Vienna, Austria.

[14 ] Department of Neurosurgery, University Hospital Cologne, Cologne, Germany.

[15 ] Department of Neurosciences, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

[16 ] Department of Oncology, Hospital Linz, Austria.

[17 ] Department of Neurosurgery, University Hospital Freiburg, Germany.

[18 ] Department of Neurosurgery, University Hospital Leipzig, Germany.

[19 ] Department of Neurosurgery, University Hospital Berlin Charité, Germany.

[20 ] Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland.

Article

Publisher Item ID: 1078-0432.CCR-14-2737

DOI: 10.1158/1078-0432.CCR-14-2737

PubMed ID: 25655102

SO-VID: aea7df7e-266e-4c95-96ae-88d9a8d3577f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 97

See all cited by